Correlation of tracer uptake in sentinel lymph nodes as measured on SPECT/CT and during intra-operative gamma tracing with SENSEI: the UZ Leuven experience

IF 2.3 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical and Translational Imaging Pub Date : 2024-08-30 DOI:10.1007/s40336-024-00654-z

Martin Manley, Sander Jentjens, Liesbeth De Wever, Christophe M. Deroose, Wouter Everaerts, Karolien Goffin

{"title":"Correlation of tracer uptake in sentinel lymph nodes as measured on SPECT/CT and during intra-operative gamma tracing with SENSEI: the UZ Leuven experience","authors":"Martin Manley, Sander Jentjens, Liesbeth De Wever, Christophe M. Deroose, Wouter Everaerts, Karolien Goffin","doi":"10.1007/s40336-024-00654-z","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>This retrospective analysis aims to study the relationship between tracer uptake in sentinel lymph nodes (SLNs) as measured on SPECT/CT and during intra-operative gamma tracing with a drop-in gamma probe (SENSEI<sup>®</sup>) in patients who participated in the UZ Leuven cohort of a prospective multicentre clinical trial evaluating the SENSEI<sup>®</sup> probe for minimally-invasive SLN biopsy (SLNB) in prostate cancer. Correlation of pre- and intraoperative imaging can allow for improved surgical planning, providing important information to guide intraoperative findings.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Nine patients with histologically proven prostate cancer scheduled for radical prostatectomy (RP) with extended pelvic lymph node dissection (ePLND) were prospectively selected for preoperative lymphoscintigraphy with SPECT/CT the day before surgery after intra-prostatic injection of 240 MBq of <sup>99m</sup>Tc-nanocolloid under ultrasound guidance. SLNB was performed with the SENSEI<sup>®</sup> drop-in gamma probe during standard of care RP with ePLND. SLN detection and counts on SPECT/CT and in vivo and ex vivo probe measurements were compared.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The patient-based detection rate of at least one SLN was 100% on SPECT/CT and 100% intraoperatively with the drop-in gamma probe. In total, 29 SLNs were detected with the probe and 32 SLNs on SPECT/CT. The correlation between SPECT/CT counts and in vivo and ex vivo probe measurements was significant but moderate (Pearson <i>r</i> = 0.57, <i>p</i> = 0.002 and <i>r</i> = 0.64, <i>p</i> = 0.0003, respectively).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Drop-in gamma probe measurements showed a moderate correlation with the SPECT/CT counts. SPECT/CT uptake values can be used as an estimate for in vivo detection of SLNs with the probe.</p>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40336-024-00654-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

This retrospective analysis aims to study the relationship between tracer uptake in sentinel lymph nodes (SLNs) as measured on SPECT/CT and during intra-operative gamma tracing with a drop-in gamma probe (SENSEI^®) in patients who participated in the UZ Leuven cohort of a prospective multicentre clinical trial evaluating the SENSEI^® probe for minimally-invasive SLN biopsy (SLNB) in prostate cancer. Correlation of pre- and intraoperative imaging can allow for improved surgical planning, providing important information to guide intraoperative findings.

Methods

Nine patients with histologically proven prostate cancer scheduled for radical prostatectomy (RP) with extended pelvic lymph node dissection (ePLND) were prospectively selected for preoperative lymphoscintigraphy with SPECT/CT the day before surgery after intra-prostatic injection of 240 MBq of ^99mTc-nanocolloid under ultrasound guidance. SLNB was performed with the SENSEI^® drop-in gamma probe during standard of care RP with ePLND. SLN detection and counts on SPECT/CT and in vivo and ex vivo probe measurements were compared.

Results

The patient-based detection rate of at least one SLN was 100% on SPECT/CT and 100% intraoperatively with the drop-in gamma probe. In total, 29 SLNs were detected with the probe and 32 SLNs on SPECT/CT. The correlation between SPECT/CT counts and in vivo and ex vivo probe measurements was significant but moderate (Pearson r = 0.57, p = 0.002 and r = 0.64, p = 0.0003, respectively).

Conclusions

Drop-in gamma probe measurements showed a moderate correlation with the SPECT/CT counts. SPECT/CT uptake values can be used as an estimate for in vivo detection of SLNs with the probe.

Abstract Image

查看原文本刊更多论文

SPECT/CT测量的前哨淋巴结示踪剂摄取量与SENSEI术中伽马示踪测量的相关性：鲁汶大学的经验

目的这项回顾性分析旨在研究SPECT/CT检测到的前哨淋巴结（SLN）示踪剂摄取量与使用滴入式伽马探头（SENSEI®）进行术中伽马示踪时的示踪剂摄取量之间的关系，研究对象是参加鲁汶大学队列前瞻性多中心临床试验的患者，该试验评估了SENSEI®探头在前列腺癌微创SLN活检（SLNB）中的应用。方法前瞻性地选择了九名经组织学证实的前列腺癌患者进行前列腺癌根治术（RP）和盆腔淋巴结清扫术（ePLND），并在超声引导下于手术前一天在前列腺内注射 240 MBq 的 99mTc-nanocolloid 后进行 SPECT/CT 术前淋巴管造影。在使用 ePLND 的标准 RP 治疗过程中，使用 SENSEI® 插入式伽马探头进行 SLNB。比较了SPECT/CT上的SLN检测和计数，以及体内和体外探针的测量结果。结果SPECT/CT上患者至少一个SLN的检测率为100%，术中使用插入式伽马探针的检测率为100%。探针共检测到 29 个 SLN，SPECT/CT 共检测到 32 个 SLN。SPECT/CT计数与体内和体外探针测量值之间的相关性显著但不明显（Pearson r = 0.57，p = 0.002 和 r = 0.64，p = 0.0003）。SPECT/CT摄取值可作为探针在体内检测SLN的估计值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Translational Imaging Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

3.60

自引率

4.80%

发文量

期刊介绍： Clinical and Translational Imaging is an international journal that publishes timely, up-to-date summaries on clinical practice and translational research and clinical applications of approved and experimental radiopharmaceuticals for diagnostic and therapeutic purposes. Coverage includes such topics as advanced preclinical evidence in the fields of physics, dosimetry, radiation biology and radiopharmacy with relevance to applications in human subjects. The journal benefits a readership of nuclear medicine practitioners and allied professionals involved in molecular imaging and therapy.